M
Mark Ledeboer
Researcher at Vertex Pharmaceuticals
Publications - 12
Citations - 356
Mark Ledeboer is an academic researcher from Vertex Pharmaceuticals. The author has contributed to research in topics: Kinase & Proto-oncogene tyrosine-protein kinase Src. The author has an hindex of 4, co-authored 11 publications receiving 349 citations.
Papers
More filters
Patent
Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
Jeremy Green,Guy W. Bemis,Anne-Laure Grillot,Mark Ledeboer,Francesco G. Salituro,Edmund Harrington,Huai Gao,Baker Christopher T,Jingrong Cao,Michael R. Hale +9 more
TL;DR: In this paper, the authors provide a compound of formula I or II:or a pharmaceutically acceptable derivative thereof, wherein R1, R2, R3, and R4 are as described in the specification.
Patent
Inhibitors of Src and Lck protein kinases
TL;DR: In this paper, the authors provided compounds of formula I: or a pharmaceutically acceptable derivative thereof, wherein A-B is N O or O O N and G, R1, R2, R3, and R4 are as described in the specification.
Patent
Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
Guy Arlington Bemis,Huai Natick Gao,Edmund Harrington,Mark Ledeboer,Francesco Marlboro Salituro,Jian Newton Wang +5 more
TL;DR: In this paper, the authors provided compounds of formula I or a pharmaceutically acceptable derivative thereof, wherein A-B is N-O or O-N and G, R?1, R2, R3, and R4? are as described in the specification.
Journal ArticleDOI
Discovery and Optimization of Highly Selective Inhibitors of CDK5.
Matthew J. Daniels,Goran Malojčić,Susan L. Clugston,Brett Williams,Marie Coeffet-Le Gal,Xing Pan-zhou,Srinivasan P. Venkatachalan,Jean-Christophe Harmange,Mark Ledeboer +8 more
TL;DR: In cellular assays, these compounds demonstrate CDK5 target engagement while avoiding anti-proliferative effects associated with inhibiting other CDKs, and exhibit promising in vivo PK profiles, enabling their use as tool compounds for interrogating the role ofCDK5 in ADPKD and other diseases.
Patent
Isoxazoles and their use in the treatment of ischemic diseases
TL;DR: In this paper, a compound of formula I, or a pharmaceutically acceptable salt thereof, is provided for the treatment of neurological, neurodegenerative, ischemic and inflammatory disorders.